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Cyclin B1 regulates the G2-M transition of the cell cycle. Cyclin B1 expression is higher in premalignant and malignant than normal
breast lesions. Correlation of cyclin B1 expression with other histopathological variables and prognostic role in breast cancer are not
fully understood. Traditionally used prognostic criteria identify large subset of patients to receive adjuvant chemotherapy and to be
exposed to adverse effects. A reliable and simple method helping prognostic evaluation in breast cancer is needed. We analysed
cyclin B1 expression on 1348 invasive breast cancers and studied correlations with other histopathological variables and survival. High
cyclin B1 correlated with high tumour grade, large tumour size and positive nodal status, oestrogen and progesterone receptor
negativity, positive HER2 and p53 status, young age at diagnosis, and high cyclin E, cyclin A and Ki67 expression. Among patients not
given adjuvant chemotherapy high cyclin B1 was a strong predictor of shorter overall and metastasis-free survival (RR 3.74, Po0.0005
and RR 3.51, Po0.0005, respectively), and remained as an independent prognostic factor also in multivariate analysis (RR 1.80,
P¼0.04 and RR 2.31, P¼0.02, respectively). This study suggests high cyclin B1 associates with aggressive phenotype and is an
independent prognostic factor in breast cancer.
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Breast cancer is a heterogeneous disease with varying biological
profile and aggressiveness. Adjuvant chemotherapy improves
breast cancer survival but can cause side effects that may
potentially have negative long-term effects on quality of life of
women surviving breast cancer. Therefore additional markers are
needed for better selection of the patients benefiting from adjuvant
treatment and to avoid overtreatment. Traditional prognostic
factors, such as tumour size, lymph node status and tumour grade
are used to identify patients with high risk for recurrence who
potentially benefit from adjuvant chemotherapy (Bast et al, 2001).
Negative hormone receptor and positive HER2 status also predict
poor outcome. A new entity, the so-called triple negative
(oestrogen receptor, progesterone receptor and HER2 negative)
breast cancer has a highly aggressive clinical course with shorter
recurrence-free and overall survival (Dent et al, 2007). High
proliferation rate has also been shown to associate with poor
breast cancer survival (Dettmar et al, 1997; Bryant et al, 1998;
Ahlin et al, 2007). Newer methods utilising complementary DNA
(cDNA) have been developed aiming at more specific prognostic
evaluation than by immunohistochemical methods (van de Vijver
et al, 2002; van’t Veer et al, 2002; Paik et al, 2004). These methods
are laborious and expensive, and are not as easily adapted for
routine use as are immunohistochemical methods.
Carefully regulated expression of cyclins and cyclin-dependent
kinases controls the cell cycle (Sherr, 1996). The cyclin B1/CDK1
complex controls the G2-M phase transition, and is needed for
initiation of mitosis (Pines and Hunter, 1990). Deregulation of
cyclin B1 causes uncontrolled cell growth and may promote
malignant transformation. p53 regulates G2-M transition through
cyclin B1 expression level (Innocente et al, 1999). In cancer cells,
cyclin B1 expression has also been detected in G1 phase (Shen et al,
2004). This continuous, unscheduled expression may lead to
substrate phosphorylation regardless of the cell-cycle phase and
thus cause uncontrolled cell-cycle progression and be one of the
mechanisms in genetic instability and carcinogenesis.
Cyclin B1 overexpression is common in several cancers
(Murakami et al, 1999; Soria et al, 2000; Nozoe et al, 2002; Takeno
et al, 2002; Yoshida et al, 2004; Ikuerowo et al, 2006). It has been
shown to associate with high-grade tumours and advanced stage of
disease, as well as poor prognosis, in several cancers including
oesophageal squamous cell (Murakami et al, 1999; Nozoe et al,
2002; Takeno et al, 2002), non-small cell lung (Soria et al, 2000;
Yoshida et al, 2004) and renal cell cancer (Ikuerowo et al, 2006).
Cyclin B1 expression level increases in the transition from
benign through premalignant to advanced malignant breast lesions
(Kawamoto et al, 1997). The first reported study of cyclin B1
expression in breast cancer comprised only 73 cancers (Winters
et al, 2001). Both nuclear and cytoplasmic expressions were
independent predictors of poor relapse-free and overall survival.
Cyclin B1 expression was not associated with tumour size, nodal
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sstatus, grade, oestrogen receptor (ER) status or p53 immunohis-
tochemical expression. In another study with 332 T1-2 N-negative
breast cancers (Ku ¨hling et al, 2003; Rudolph et al, 2003), high
cyclin B1 expression associated with high grade, high Ki67, cyclin
A and E expression, and ER and progesterone receptor (PR)
negativity and predicted relapse-free and overall survival in
univariate analysis but was not an independent prognostic factor
in multivariate analysis including Ki67 as a covariate (Rudolph
et al, 2003). Among the 273 tumours treated with surgery and
postoperative radiation only, cyclin B1 was an independent
predictor of poor overall survival among premenopausal but not
postmenopausal or all patients (Ku ¨hling et al, 2003). A further
study with 56 invasive stage I–II cancers did not show any
association between cyclin B1 expression and prognosis (Peters
et al, 2004). A recent study with 109 breast cancers suggested that
nuclear cyclin B1 expression was an independent prognostic factor
(Suzuki et al, 2007).
The studies of cyclin B1 expression in breast cancer strongly
suggest a prognostic role but these studies have been rather small.
In this study we investigated cyclin B1 expression, its correlation
with other histopathological features and survival in an extensive
series of 1348 breast cancers (779 cancers in survival analysis).
MATERIALS AND METHODS
Patients
The study consists of 1348 invasive breast cancers. Of these, 884
are unselected patients treated at the Department of Oncology,
Helsinki University Central Hospital between 1997–1998 and 2000
(79% of all consecutive, newly diagnosed breast cancer cases
during the collection periods; Syrja ¨koski et al, 2000; Kilpivaara
et al, 2005). The rest of the patients are familial breast cancer
patients identified by systematic screening at the Department of
Oncology, Helsinki University Central Hospital or ascertained
through genetic counselling at the Department of Clinical Genetics
(Eerola et al, 2000). Of all patients, 439 are sporadic, 456 have
strong family history (at least three first or second degree relatives
with breast or ovarian cancer, including the proband), 342 have
family history of two affected first degree relatives (including the
proband) and 53 patients are BRCA1 and 58 BRCA2 mutation
carriers.
Information on tumour histology, grade, size, nodal status,
distant metastases, ER and PR status were obtained from patho-
logy reports (Eerola et al, 2005). An expert breast cancer patho-
logist re-reviewed all tumours for histology and grade. Grading
was performed according to Scarff–Bloom–Richardson modified
by Elston and Ellis. Patient characteristics are shown in Table 1.
Tissue microarray (TMA) construction has been described earlier
(Eerola et al, 2005). HER2 expression was analysed by immuno-
histochemical staining and gene amplification by chromogenic
in situ hybridisation on TMAs (Tanner et al, 2000; Lassus et al,
2004), and p53 (Tommiska et al, 2005), cyclin A (Aaltonen et al,
2006) and Ki67 (Ahlin et al, 2007) protein expression by
immunohistochemical staining as previously described.
Immunohistochemistry
After deparaffinisation in xylene and hydration in graded alcohols,
cyclin B1 immunostaining was done in automated immunostainer
(Ventana Medical Systems Inc., Tucson, AZ, USA) using a diamino-
benzidine kit and amplification kit (Ventana) to ensure standardised
performance. Cyclin B1 antibody (Novocastra, Newcastle-upon-Tyne,
UK) was diluted 1:40 and antigen retrieval was done using the iView
kit (Ventana). Only unequivocal positive nuclear or cytoplasmic
staining was accepted as a positive reaction, and cyclin B1 result was
the percentage of tumour cells displaying cytoplasmic or nuclear
Table 1 Patient and tumour characteristics
Grade
1 318 (23.6%)
2 606 (45.0%)
3 399 (29.6%)
Not known 25 (1.9%)
Tumour size (T)
1 782 (58.0%)
2 448 (33.2%)
3 51 (3.8%)
4 38 (2.8%)
NA 29 (2.2%)
Nodal status (N)
Positive 585 (43.4%)
Negative 731 (54.2%)
NA 32 (2.4%)
Primary metastases (N)
Positive 48 (3.6%)
Negative 1244 (92.3%)
NA 56 (4.2%)
Clinical stage
I 503 (37.3%)
II 659 (48.9%)
III 58 (4.3%)
IV 48 (3.6%)
NA 80 (5.9%)
Oestrogen receptor (ER)
Positive 989 (73.4%)
Negative 288 (21.4%)
NA 71 (5.3%)
Progesterone receptor (PR)
Positive 828 (61.4%)
Negative 448 (33.2%)
NA 72 (5.3%)
Tumour pathology
Ca ductale 924 (68.5%)
Ca lobulare 254 (18.8%)
Ca medullare 20 (1.5%)
Ca mucinosum 25 (1.9%)
Ca papillare 4 (0.3%)
Ca tubulare 46 (3.4%)
Others 75 (5.6%)
HER2
Positive 155 (11.5%)
Negative 1074 (79.7%)
NA 119 (8.8%)
p53
Positive 253 (18.8%)
Negative 989 (73.4%)
NA 106 (7.9%)
Ki67 expression
o5% 318 (23.6%)
5–19% 553 (41.0%)
20–29% 220 (16.3%)
429% 214 (15.9%)
NA 43 (3.2%)
Age at diagnosis
o50 years 493 (36.6%)
X50 years 855 (63.4%)
Menopausal status
Premenopausal 297 (22.0%)
Postmenopausal 568 (42.1%)
NA 483 (35.8%)
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simmunoreactivity. Normal breast tissue specimen was used as
negative and human palatine tonsil tissue specimen as positive
control for cyclin B1. Minimum of 500 tumour cells on each tumour
was calculated ( 40 objective). One investigator analysed the
TMAs. All scoring was done under the supervision of an expert
breast cancer pathologist. Result was obtained from 1100 tumours
(81.4%). Cyclin B1 median value was 5.0%, range 0–71.5%,
standard deviation 6.39 and standard error 0.19. Cyclin B1
expression followed the normal distribution.
The follow-up data
Information on adjuvant treatment and distant metastases during
the follow-up was collected from the patient records. The
information on death due to breast cancer or other reason was
obtained from the Finnish Cancer Registry. Survival was analysed
as metastasis-free survival (MFS): the time from the date of
primary surgery to the date of radiological confirmed distant
metastases, and as overall survival (OS): the time from the date of
primary surgery to the date of death due to breast cancer. A total of
797 patients were accepted for survival analysis: including the
unselected series and familial patients ascertained to the familial
breast cancer study at the diagnosis or within 6 months after
diagnosis. Of these 797 patients, 796 (99.9%) underwent surgery,
691 (87%) received adjuvant radiotherapy, 323 (41%) adjuvant
chemotherapy and 359 (45%) adjuvant endocrine treatment. Of the
patients that were given adjuvant chemotherapy, 163 (50%) were
treated with CMF (cyclophosphamide-methotrexate-5-fluoro-
uracil), 102 (32%) with CEF (cyclophosphamide-epirubicin-5-
fluorouracil) and 58 (18%) with some other chemotherapy
regimen. Chemotherapy, endocrine treatment and radiation were
given postoperative. Treatment decisions were made according to
standard guidelines at that time. The median follow-up time was
93 months (2–516 months). Of all the patients in the survival
analysis, 127 (16%) relapsed with distant metastases during the
follow-up time, of whom 91 (11%) died from breast cancer.
Statistical analyses
Statistical analyses were assessed with SPSS for Windows v12.0.1
(SPSS Inc., Chicago, IL, USA) and SISA (http://home.clara.net/sisa/).
Correlation of cyclin B1 expression (as a continuous variable) and
other histopathological features was assessed with Mann–Whitney
U-test (dichotomised variables) or Spearman’s s-correlation test
(continuous variables). The frequencies of cyclin B1 positive tumours
among patient groups with different familial background were
compared with w
2-test. A study investigating the optimal cut-off
values of cyclin A and Ki67 for prognostic evaluation suggested that
cut-off value around the 7th decile gives best separation between
slowly and rapidly proliferating tumours (Ahlin et al, 2007). The
relative risk (RR) for MFS and OS with 95% confidence interval (CI)
using the Cox proportional hazard model was calculated for cyclin B1
dichotomised at 7th decile (cut-off value 5.6%). Kaplan–Meier curves
were constructed for survival comparing the subsets of cases using a
log-rank test. All P-values are two-sided and significance level is 0.05.
Ethics
This study was performed with informed consent from the patients
as well as permission from the Ethics Committee of the Helsinki
University Central Hospital and from the Ministry of Social Affairs
and Health in Finland.
RESULTS
High cyclin B1 expression was associated with large tumour size,
positive nodal status, advanced clinical stage, high grade, ER and
PR negativity, positive p53, HER2, and Ki67 status, high cyclin A
and cyclin E expression, younger age at disease onset, and
premenopausal status. Furthermore high cyclin B1 expression was
significantly more common among triple-negative tumours. Cyclin
B1 and D1 expressions did not correlate. Table 2 shows the
correlations between cyclin B1 and other tumour features. Ductal
and medullary histology were significantly more common among
tumours with high than low cyclin B1 expression (Po0.0005 and
P¼0.0008, respectively), and lobular histology among tumours
with low cyclin B1 expression (Po0.0005).
Tumours with the highest cyclin B1 expression (410%) were
more frequent among BRCA1 than sporadic (OR 2.8, 95% CI
1.4–5.6, P¼0.003) or familial BRCA1/2 mutation negative (OR 4.8,
95% CI 2.3–9.9, Po0.0005) patients. Cyclin B1 expression among
BRCA2-related tumours did not significantly differ from expres-
sion among tumours of sporadic or familial non-BRCA1/2 patients
but tumours of sporadic patients showed more often cyclin B1
expression above 10% than tumours of familial non-BRCA1/2
patients (OR 1.7, 95% CI 1.1–2.7, P¼0.02).
The RRs for OS and MFS were assessed with cyclin B1
dichotomised at 7th decile (5.6%), because we have earlier shown
that this is the optimal cut-off for proliferation markers (Ahlin
et al, 2007). This corresponds to the proportion of grade 3 tumours
in our material. The RR for poor survival was 3.74 (95% CI 1.96–
7.12, Po0.0005) and for metastasis 3.51 (95% CI 2.05–6.01,
Po0.0005) among chemotherapy-naive patients (Table 3). Among
Table 2 Correlation of cyclin B1 expression and other tumour
characteristics (Spearman’s s-correlation test)
Correlation
coefficient 95% CI P value
Tumour size (T) 0.163 0.104–0.221 o0.0005
Nodal status (N) 0.081 0.021–0.140 0.008
Primary metastases (M) 0.018  0.042–0.078 0.56
Clinical stage 0.129 0.075–0.183 o0.0005
Tumour grade 0.493 0.447–0.537 o0.0005
Oestrogen receptor (ER)  0.327  0.380–  0.272 o0.0005
Progesterone receptor (PR)  0.216  0.273–  0.157 o0.0005
HER2 0.245 0.188–0.301 o0.0005
Triple negativity  0.275 –0.329–  0.220 o0.0005
Ki67 0.528 0.484–0.570 o0.0005
p53 0.311 0.256–0.364 o0.0005
Age at onset  0.156  0.213–  0.098 o0.0005
Menopausal status  0.164  0.228–  0.098 o0.0005
Cyclin E 0.392 0.340–0.442 o0.0005
Cyclin D1 0.021  0.039–0.081 0.50
Cyclin A 0.610 0.571–0.646 o0.0005
Abbreviation: 95% CI¼95% confidence interval. Cyclin B1 analysed as a continuous
variable. *P value assessed with the Mann–Whitney U-test.
Table 3 Cyclin B1 expression and survival in univariate analysis
(Cox regression analysis)
RR 95% CI P value
(A) Metastasis-free survival
Chemotherapy naive patients (n¼473) 3.51 2.05–6.01 o0.0005
All patients (n¼797) 2.48 1.72–3.57 o0.0005
Chemotherapy patients (n¼323) 1.58 0.96–2.60 0.07
(B) Overall survival
Chemotherapy naive patients (n¼473) 3.74 1.96–7.12 o0.0005
All patients (n¼797) 2.58 1.82–3.90 o0.0005
Chemotherapy patients (n¼323) 1.56 0.87–2.80 0.13
Abbreviations: RR¼relative risk; 95% CI¼95% confidence interval. Cyclin B1
dichotomised at 7th percentile (5.6%).
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sthe subgroup of patients that had received chemotherapy, the
association with poor MFS was weaker (RR 1.58, 95% CI 0.96–2.60,
P¼0.07) and no significant association with poor OS was found
(RR 1.56, 95% CI 0.87–2.80, P¼0.13). Endocrine treatment did
not seem to affect the association of cyclin B1 with survival. RR for
poor survival was 3.09 (95% CI 1.68–5.68, Po0.0005) among the
patients that had received endocrine treatment and 2.24 (95% CI
1.21–4.14, P¼0.01) among the patients that had not received
endocrine treatment. The RRs for metastases were 3.08 (95% CI
1.83–5.18, Po0.0005) and 2.06 (95% CI 1.24–3.43, P¼0.006),
respectively. The association with survival was similar when cyclin
B1 was analysed as a continuous value (data not shown). In
Figure 1, Kaplan–Meier curves show OS and MFS for cyclin B1
dichotomised at 5.6%.
A multivariate model including TNM status, tumour grade, and
ER, PR, Ki67, p53 and HER2 status was constructed to analyse the
independent impact of cyclin B1 expression on prognosis. High
cyclin B1 had an independent association with poor outcome
(Table 4). Among chemotherapy-naive patients, the associations
were also stronger in multivariate analysis. With tumour size
and nodal status, cyclin B1 was the only factor independently
associated with poor MFS (RR 2.31, 95% CI 1.17–4.59, P¼0.016)
and OS (RR 1.79, 95% CI 1.28–4.14, P¼0.04).
DISCUSSION
This study is so far the most extensive study of cyclin B1
expression in breast cancer and shows that high cyclin B1
expression is a predictor of poor overall and metastasis-free
survival. Associations with poor prognosis were stronger among
chemotherapy-naive patients. Besides positive nodal status and
large tumour size, high cyclin B1 expression was the only
independent factor predicting poor OS and MFS among chemo-
therapy-naive patients. These results suggest that cyclin B1 is a
strong independent prognostic marker that could add to accuracy
of prognostic evaluation made by traditional prognostic markers
and that could easily be adapted for routine use.
Relative risk for poor survival for cyclin B1 was 3.74 and the
risk for metastasis 3.51 among chemotherapy-naive patients.
In this study, cyclin B1 was a stronger marker of poor prognosis
than proliferation markers cyclin A or Ki67 (among chemo-
therapy-naive patients the RR for poor survival in univariate
analysis was 2.47 for cyclin A and 1.90 for Ki67) and the risk for
poor survival was also stronger than that has been previously
reported for Ki67 or cyclin A. In multivariate analysis among
chemotherapy-naive patients, high cyclin B1 was almost as strong
predictor of poor OS as HER2 and PR status, or even tumour
grade, and it predicted poor MFS more powerfully than HER2 and
PR status or tumour grade. The independent prognostic value of
cyclin B1 in this study was as strong as or even stronger than the
risks reported for commonly used biological markers in breast
cancer. The independent relative risk for histological grade has
been reported to be approximately 1.70–3.20 (Simpson et al, 2000;
Elston and Ellis, 2002; Volpi et al, 2004), for HER2 2.56 (Joensuu
et al, 2003), and for the tumour-related proteolytic factors uPA and
PAI-1 in a pooled analysis from 18 patient populations 2.58–3.12
(Look et al, 2002). In a recent study tumour triple negative status
had RR 1.8 for mortality and RR 1.5 for metastasis (Dent et al,
2007). Gene expression profiles have been suggested to add
specificity to prognostic evaluation made by traditional and
immunohistochemical markers. In a validation study, perhaps
the most extensively studied profile, the 70-gene prognosis
signature predicted metastases with RR of 2.13 (95% CI 1.19–
3.82) and mortality with RR of 2.63 (95% CI 1.45–4.79) (Buyse
et al, 2006). Thus high cyclin B1 might be a biological risk
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Figure 1 Kaplan–Meier curves showing metastasis-free and overall survival for cyclin B1 dichotomised at 5.6% (7th decile). (A) Metastasis-free survival
among chemotherapy-naive patients (n¼473). (B) Metastasis-free survival among patients having received adjuvant chemotherapy (n¼323). (C) Overall
survival among chemotherapy-naive patients (n¼473). (D) Overall survival among patients having received adjuvant chemotherapy (n¼473). Kaplan–
Meier curves constructed and P-values counted comparing the subsets of cases using a log-rank test.
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spredictor as strong as the 70-gene profile and more easily adapted
for routine use.
Our study is the largest so far showing the association of high
cyclin B1 and shorter survival in breast cancer. One earlier smaller
study with stage I–II tumours did not show any association (Peters
et al, 2004), one with 109 tumours showed association with only
nuclear staining (Suzuki et al, 2007) and one with 73 tumours
showed a significant association (Winters et al, 2001). In the
hitherto largest study of 332 tumours, all N-negative, cyclin B1 was
associated with poor prognosis but not in multivariate analysis
including Ki67 (Rudolph et al, 2003), and when 273 tumours with
only surgery and postoperative radiation were analysed, cyclin B1
was prognostic only in premenopausal patients (Ku ¨hling et al,
2003). The limitations of our study include the retrospective
setting of the study and the heterogeneity of the patient material
concerning adjuvant treatments. Conclusions are, however, in line
with the ones suggested by earlier smaller studies, and we feel the
role of cyclin B1 as prognostic factor in breast cancer deserves to
be further validated, utilising specifically the methods and cut-offs
designed in this study.
The correlations between cyclin B1 and other tumour features
show that high cyclin B1 expression is common among tumours
with an aggressive phenotype. The association of high cyclin B1
expression with large tumour size, positive nodal status, high
grade, and ER and PR negativity is similar to previous reported
data (Ku ¨hling et al, 2003; Rudolph et al, 2003). One smaller study
did not find any correlation to N, T, ER and p53 status, but the
small sample size (73 tumours) may explain this discrepancy
(Winters et al, 2001). In our study, again supported by earlier
results, cyclin B1 was strongly associated with high grade and high
Ki67, cyclin A and E expression (Winters et al, 2001). We also
show that high cyclin B1 associated with p53 positivity. This is
biologically relevant because p53 controls the cell cycle via cyclin
B1 (Innocente et al, 1999). Thus multiple biological factors related
with an active cell cycle are intercorrelated. Cyclin B1 expression
correlated significantly with HER2 positivity and this, to our
knowledge, has not been reported earlier and is consistent with an
aggressive phenotype. One can speculate on whether the prog-
nostic impact of cyclin B1 reflects only a high tumour proliferation
rate or whether high cyclin B1 may reflect also other biological
properties of the tumour. In our patients cyclin B1 seems to be a
stronger prognostic factor than cyclin A or Ki67. In our material
(data not shown), a high cyclin A or Ki67 score was associated with
a shorter time to first event among patients eventually developing
metastases, whereas the median time to development of metastases
was similar in patients with high and low cyclin B1 score. This
implies cyclin B1 expression may not be a pure proliferation
marker but reflects also other features, for exqample, genomic
instability of the tumour as suggested by previous studies
(Innocente et al, 1999; Shen et al, 2004). By analysing both
cytoplasmic and nuclear cyclin B1 expression in this study, both
aberrant and physiologic cyclin B1 expression were probably
included because the cyclin B1/CDK1 complex is relocated to the
nucleus only in the beginning of the M phase.
In conclusion, this study shows that cyclin B1 expression is an
independent predictor of poor overall and metastasis-free survival
in breast cancer. If verified the results of this study suggest cyclin
B1 immunohistochemistry is a method that could easily be adapted
for routine use as a prognostic marker in breast cancer. The
generally lower risk ratios for mortality or metastases in patients
given adjuvant chemotherapy suggest that high cyclin B1 score
may indicate an enhanced sensitivity to chemotherapy.
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Oestrogen receptor 0.89 0.45–1.76 0.74
(B) Metastasis-free survival
Chemotherapy naive patients (n¼473)
Nodal status 2.76 1.48–5.13 0.001
Cyclin B1 2.31 1.17–4.59 0.02
Tumour size 1.91 1.35–2.72 o0.0005
Grade 1.44 0.90–2.32 0.13
Ki67 1.39 0.82–1.65 0.35
Progesterone receptor 1.27 0.60–2.67 0.53
Oestrogen receptor 1.10 0.36–3.36 0.87
HER2 1.10 0.46–2.63 0.82
p53 1.06 0.72–1.55 0.79
All patients (n¼797)
Nodal status 2.97 1.87–4.67 o0.0005
Cyclin B1 1.68 1.02–2.74 0.04
Tumour size 1.64 1.33–2.03 o0.0005
Grade 1.63 1.14–2.32 0.008
HER2 1.46 0.92–2.31 0.11
Progesterone receptor 1.39 0.84–2.31 0.20
Ki67 1.26 0.67–1.52 0.26
p53 1.14 0.92–1.41 0.23
Oestrogen receptor 0.81 0.45–1.47 0.49
Abbreviations: RR¼relative risk; 95% CI¼95% confidence interval. Cyclin B1
dichotomised at 7th percentile (5.6%).
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